根据复发预测值确定IB期胃癌高风险患者的化疗益处:一项多中心回顾性研究
Qi-Chen He1, Ze-Ning Huang1, Yu-Bin Ma2
1Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China; Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China; Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou, China; Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China.
这项研究开发了一种复发预测值 (RPV),以确定从辅助化疗 (AC) 中受益的IB期胃癌患者. 患有高RPV的高风险患者在AC治疗中表现出更好的生存率,从而实现了个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 胃肠道手术 胃肠道手术
- 临床研究 临床研究
背景情况:
- IB期胃癌在预测复发风险方面存在挑战.
- 确定从辅助化疗 (AC) 中受益的患者对于个性化治疗至关重要.
研究的目的:
- 开发和验证复发预测值 (RPV) 以精确评估IB期胃癌复发风险.
- 识别那些可能受益于辅助化疗的高风险患者.
主要方法:
- 一个多中心的, 555 (培训) 和409 (验证) 阶段IB胃癌患者的回顾性研究.
- 高风险因素 (HR+) 包括差分化的瘤,淋巴血管侵袭,围神经侵袭或年龄<50岁.
- 通过加权这些因素来分层患者,开发了复发预测值 (RPV).
主要成果:
- RPV有效地将患者分为不同的风险组,在3年无复发生存期 (RFS) 中存在显著差异.
- 只有患有高RPV的高风险患者,在辅助化疗 (AC) 时,RFS显著改善.
- 基于RPV的诺米图显示出良好的预测准确性 (C指数0.748培训,0.711验证).
结论:
- 复发预测值 (RPV) 是识别IB期胃癌患者从辅助化疗中受益的有价值的工具.
- RPV帮助外科医生制定个性化治疗策略,以改善患者的治疗结果.
更多相关视频
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...


